Ren, Shijie http://orcid.org/0000-0003-3568-7124
Bermejo, Iñigo
Simpson, Emma
Wong, Ruth
Scott, David L.
Young, Adam
Stevenson, Matt
Funding for this research was provided by:
National Institute for Health Research (16/56/23)
Article History
First Online: 3 March 2018
Compliance with Ethical Standards
:
: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 16/56/23). Visit the HTA programme website for further project information (ExternalRef removed).
: David L. Scott has no conflicts of interest relating to baricitinib; however, his department has received a peer-reviewed grant from Pfizer within the last 12 months to undertake academic research on polypharmacy in arthritis. The department has also received free ETN from Pfizer to use in an NIHR-funded programme grant in RA. David L. Scott and Matt Stevenson declare that they have written a commentary on Janus kinase inhibitors for The Lancet (ExternalRef removed), which was written after the completion of this STA. Shijie Ren, Iñigo Bermejo, Emma Simpson, Ruth Wong, and Adam Young have no conflicts of interest to declare.